- Home
- FHTX vs NYXH Comparison
FHTX vs NYXH Comparison
Compare FHTX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FHTX | NYXH |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.1M | 137.5M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FHTX | NYXH |
|---|---|---|
| Price | $2.03 | $0.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $4.17 | ★ $4.20 |
| AVG Volume (30 Days) | ★ 1.2M | 217.2K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,909,000.00 | N/A |
| Revenue This Year | N/A | $275.91 |
| Revenue Next Year | $15.98 | $93.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $1.79 | $0.80 |
| 52 Week High | $7.61 | $5.92 |
Technical Indicators
Market Signals| Indicator | FHTX | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 25.12 | 23.47 |
| Support Level | $1.79 | N/A |
| Resistance Level | $5.27 | $1.69 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.11 | -0.05 |
| Stochastic Oscillator | 61.43 | 5.85 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.